---
document_datetime: 2025-12-02 05:01:23
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/trulicity.html
document_name: trulicity.html
version: success
processing_time: 0.1143388
conversion_datetime: 2025-12-29 21:51:33.588397
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Trulicity

[RSS](/en/individual-human-medicine.xml/65999)

##### Authorised

This medicine is authorised for use in the European Union

dulaglutide Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Trulicity](#news-on)
- [More information on Trulicity](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Trulicity is a medicine used in adults and children from 10 years of age with type 2 diabetes. It is used in addition to appropriate diet and exercise.

Trulicity is used:

- on its own when use of metformin (another medicine for type 2 diabetes) is not recommended;
- as an 'add-on' to other diabetes medicines.

Trulicity contains the active substance dulaglutide.

Expand section

Collapse section

## How is Trulicity used?

Trulicity can only be obtained with a prescription. It is available as prefilled pens containing a solution to be injected under the skin in the abdomen (belly), in the thigh or in the upper arm.

For more information about using Trulicity, see the package leaflet or contact your doctor or pharmacist.

## How does Trulicity work?

The active substance in Trulicity, dulaglutide, is a 'GLP-1 receptor agonist'. It acts in the same way as GLP-1 (a hormone produced in the gut) by increasing the amount of insulin that the pancreas releases in response to food. This helps to control blood glucose levels and symptoms of type 2 diabetes.

## What benefits of Trulicity have been shown in studies?

In adults, the effectiveness of Trulicity has been studied in 5 main studies involving over 4,500 patients with type 2 diabetes. In these studies, Trulicity was compared with placebo (a dummy treatment) or with other diabetes medicines when used alone or as an add-on to various combination treatments. Information from a supportive study sent with the application was also considered.

The main measure of effectiveness was the change in the level of glycosylated haemoglobin (HbA1c), which is the percentage of haemoglobin in the blood that has glucose attached to it. HbA1c gives an indication of how well blood glucose is controlled. The patients' HbA1c at baseline ranged from 7.6 to 8.5% and patients were treated for at least 52 weeks.

Trulicity was more effective than metformin at reducing HbA1c levels when used alone, and it was more effective than the diabetes medicines exenatide (given twice daily) or sitagliptin, and at least as good as insulin glargine, when used as add-on to other treatments.

After 26 weeks of treatment, Trulicity reduced HbA1c by between 0.71 and 1.59 percentage points at the lower dose, and by between 0.78 and 1.64 percentage points at the higher dose. This was considered clinically meaningful and there was evidence that HbA1c levels remained low during long-term treatment. About 51% of those given the lower dose and 60% of patients given the higher dose of Trulicity achieved a target HbA1c below 7.0% and this was generally more than the proportion achieving this target with alternative treatments.

A further study in 9,901 adults with type 2 diabetes found Trulicity effective at reducing major harmful effects on the heart and the circulatory system. Stroke, heart attack or death from heart of circulatory problems occurred in 12.0% of patients receiving Trulicity over about 5 years compared with 13.4% of patients receiving placebo.

The benefits of Trulicity were also investigated in one main study involving 154 children from 10 years of age with type 2 diabetes. After 26 weeks of treatment, patients on Trulicity had a reduction in HbA1c levels of 0.7 percentage points, versus an increase of 0.6 percentage points for patients on placebo. This difference between Trulicity and placebo was considered clinically meaningful.

## What are the risks associated with Trulicity?

The most common side effects with Trulicity (which may affect more than 1 in 10 people) are nausea (feeling sick), vomiting and diarrhoea. For the full list of side effects and restrictions of Trulicity, see the package leaflet.

## Why is Trulicity authorised in the EU?

The European Medicines Agency decided that Trulicity's benefits are greater than its risks and it can be authorised for use in the EU. The medicine was effective for treating type 2 diabetes: it improved control of blood sugar levels in adults and children from 10 years of age and was shown to reduce harmful effects on the heart and blood circulation in adults. In addition, Trulicity has the advantage that it can be given once a week. The medicine's side effects are considered manageable.

## What measures are being taken to ensure the safe and effective use of Trulicity?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Trulicity have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Trulicity are continuously monitored. Side effects reported with Trulicity are carefully evaluated and any necessary action taken to protect patients.

## Other information about Trulicity

Trulicity received a marketing authorisation valid throughout the EU on 21 November 2014.

Trulicity : EPAR - Medicine overview

Reference Number: EMA/61283/2023

English (EN) (106.03 KB - PDF)

**First published:** 19/12/2014

**Last updated:** 16/03/2023

[View](/en/documents/overview/trulicity-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-659)

български (BG) (133.15 KB - PDF)

**First published:**

19/12/2014

**Last updated:**

16/03/2023

[View](/bg/documents/overview/trulicity-epar-medicine-overview_bg.pdf)

español (ES) (119.54 KB - PDF)

**First published:**

19/12/2014

**Last updated:**

16/03/2023

[View](/es/documents/overview/trulicity-epar-medicine-overview_es.pdf)

čeština (CS) (125.68 KB - PDF)

**First published:**

19/12/2014

**Last updated:**

16/03/2023

[View](/cs/documents/overview/trulicity-epar-medicine-overview_cs.pdf)

dansk (DA) (119.06 KB - PDF)

**First published:**

19/12/2014

**Last updated:**

16/03/2023

[View](/da/documents/overview/trulicity-epar-medicine-overview_da.pdf)

Deutsch (DE) (124.34 KB - PDF)

**First published:**

19/12/2014

**Last updated:**

16/03/2023

[View](/de/documents/overview/trulicity-epar-medicine-overview_de.pdf)

eesti keel (ET) (110.14 KB - PDF)

**First published:**

19/12/2014

**Last updated:**

16/03/2023

[View](/et/documents/overview/trulicity-epar-medicine-overview_et.pdf)

ελληνικά (EL) (131.18 KB - PDF)

**First published:**

19/12/2014

**Last updated:**

16/03/2023

[View](/el/documents/overview/trulicity-epar-medicine-overview_el.pdf)

français (FR) (124.71 KB - PDF)

**First published:**

19/12/2014

**Last updated:**

16/03/2023

[View](/fr/documents/overview/trulicity-epar-medicine-overview_fr.pdf)

hrvatski (HR) (122.02 KB - PDF)

**First published:**

19/12/2014

**Last updated:**

16/03/2023

[View](/hr/documents/overview/trulicity-epar-medicine-overview_hr.pdf)

italiano (IT) (121.39 KB - PDF)

**First published:**

19/12/2014

**Last updated:**

16/03/2023

[View](/it/documents/overview/trulicity-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (130.65 KB - PDF)

**First published:**

19/12/2014

**Last updated:**

16/03/2023

[View](/lv/documents/overview/trulicity-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (123.79 KB - PDF)

**First published:**

19/12/2014

**Last updated:**

16/03/2023

[View](/lt/documents/overview/trulicity-epar-medicine-overview_lt.pdf)

magyar (HU) (123.44 KB - PDF)

**First published:**

19/12/2014

**Last updated:**

16/03/2023

[View](/hu/documents/overview/trulicity-epar-medicine-overview_hu.pdf)

Malti (MT) (126.92 KB - PDF)

**First published:**

19/12/2014

**Last updated:**

16/03/2023

[View](/mt/documents/overview/trulicity-epar-medicine-overview_mt.pdf)

Nederlands (NL) (121.99 KB - PDF)

**First published:**

19/12/2014

**Last updated:**

16/03/2023

[View](/nl/documents/overview/trulicity-epar-medicine-overview_nl.pdf)

polski (PL) (124.29 KB - PDF)

**First published:**

19/12/2014

**Last updated:**

16/03/2023

[View](/pl/documents/overview/trulicity-epar-medicine-overview_pl.pdf)

português (PT) (121.2 KB - PDF)

**First published:**

19/12/2014

**Last updated:**

16/03/2023

[View](/pt/documents/overview/trulicity-epar-medicine-overview_pt.pdf)

română (RO) (124.43 KB - PDF)

**First published:**

19/12/2014

**Last updated:**

16/03/2023

[View](/ro/documents/overview/trulicity-epar-medicine-overview_ro.pdf)

slovenčina (SK) (124.35 KB - PDF)

**First published:**

19/12/2014

**Last updated:**

16/03/2023

[View](/sk/documents/overview/trulicity-epar-medicine-overview_sk.pdf)

slovenščina (SL) (121.63 KB - PDF)

**First published:**

19/12/2014

**Last updated:**

16/03/2023

[View](/sl/documents/overview/trulicity-epar-medicine-overview_sl.pdf)

Suomi (FI) (118.43 KB - PDF)

**First published:**

19/12/2014

**Last updated:**

16/03/2023

[View](/fi/documents/overview/trulicity-epar-medicine-overview_fi.pdf)

svenska (SV) (117.83 KB - PDF)

**First published:**

19/12/2014

**Last updated:**

16/03/2023

[View](/sv/documents/overview/trulicity-epar-medicine-overview_sv.pdf)

Trulicity : EPAR - Risk-management-plan summary

English (EN) (210.22 KB - PDF)

**First published:** 19/12/2014

**Last updated:** 16/03/2023

[View](/en/documents/rmp-summary/trulicity-epar-risk-management-plan-summary_en.pdf)

## Product information

Trulicity : EPAR - Product information

English (EN) (2.25 MB - PDF)

**First published:** 19/12/2014

**Last updated:** 31/07/2025

[View](/en/documents/product-information/trulicity-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-185)

български (BG) (2.41 MB - PDF)

**First published:**

19/12/2014

**Last updated:**

31/07/2025

[View](/bg/documents/product-information/trulicity-epar-product-information_bg.pdf)

español (ES) (1.8 MB - PDF)

**First published:**

19/12/2014

**Last updated:**

31/07/2025

[View](/es/documents/product-information/trulicity-epar-product-information_es.pdf)

čeština (CS) (1.85 MB - PDF)

**First published:**

19/12/2014

**Last updated:**

31/07/2025

[View](/cs/documents/product-information/trulicity-epar-product-information_cs.pdf)

dansk (DA) (2.44 MB - PDF)

**First published:**

19/12/2014

**Last updated:**

31/07/2025

[View](/da/documents/product-information/trulicity-epar-product-information_da.pdf)

Deutsch (DE) (2.2 MB - PDF)

**First published:**

19/12/2014

**Last updated:**

31/07/2025

[View](/de/documents/product-information/trulicity-epar-product-information_de.pdf)

eesti keel (ET) (1.95 MB - PDF)

**First published:**

19/12/2014

**Last updated:**

31/07/2025

[View](/et/documents/product-information/trulicity-epar-product-information_et.pdf)

ελληνικά (EL) (2.25 MB - PDF)

**First published:**

19/12/2014

**Last updated:**

31/07/2025

[View](/el/documents/product-information/trulicity-epar-product-information_el.pdf)

français (FR) (1.38 MB - PDF)

**First published:**

19/12/2014

**Last updated:**

31/07/2025

[View](/fr/documents/product-information/trulicity-epar-product-information_fr.pdf)

hrvatski (HR) (2.92 MB - PDF)

**First published:**

19/12/2014

**Last updated:**

31/07/2025

[View](/hr/documents/product-information/trulicity-epar-product-information_hr.pdf)

íslenska (IS) (2.55 MB - PDF)

**First published:**

19/12/2014

**Last updated:**

31/07/2025

[View](/is/documents/product-information/trulicity-epar-product-information_is.pdf)

italiano (IT) (2.47 MB - PDF)

**First published:**

19/12/2014

**Last updated:**

31/07/2025

[View](/it/documents/product-information/trulicity-epar-product-information_it.pdf)

latviešu valoda (LV) (2.04 MB - PDF)

**First published:**

19/12/2014

**Last updated:**

31/07/2025

[View](/lv/documents/product-information/trulicity-epar-product-information_lv.pdf)

lietuvių kalba (LT) (2.52 MB - PDF)

**First published:**

19/12/2014

**Last updated:**

31/07/2025

[View](/lt/documents/product-information/trulicity-epar-product-information_lt.pdf)

magyar (HU) (1.88 MB - PDF)

**First published:**

19/12/2014

**Last updated:**

31/07/2025

[View](/hu/documents/product-information/trulicity-epar-product-information_hu.pdf)

Malti (MT) (2.54 MB - PDF)

**First published:**

19/12/2014

**Last updated:**

31/07/2025

[View](/mt/documents/product-information/trulicity-epar-product-information_mt.pdf)

Nederlands (NL) (2.44 MB - PDF)

**First published:**

19/12/2014

**Last updated:**

31/07/2025

[View](/nl/documents/product-information/trulicity-epar-product-information_nl.pdf)

norsk (NO) (2.13 MB - PDF)

**First published:**

19/12/2014

**Last updated:**

31/07/2025

[View](/no/documents/product-information/trulicity-epar-product-information_no.pdf)

polski (PL) (1.84 MB - PDF)

**First published:**

19/12/2014

**Last updated:**

31/07/2025

[View](/pl/documents/product-information/trulicity-epar-product-information_pl.pdf)

português (PT) (2.29 MB - PDF)

**First published:**

19/12/2014

**Last updated:**

31/07/2025

[View](/pt/documents/product-information/trulicity-epar-product-information_pt.pdf)

română (RO) (2.31 MB - PDF)

**First published:**

19/12/2014

**Last updated:**

31/07/2025

[View](/ro/documents/product-information/trulicity-epar-product-information_ro.pdf)

slovenčina (SK) (2.07 MB - PDF)

**First published:**

19/12/2014

**Last updated:**

31/07/2025

[View](/sk/documents/product-information/trulicity-epar-product-information_sk.pdf)

slovenščina (SL) (2.73 MB - PDF)

**First published:**

19/12/2014

**Last updated:**

31/07/2025

[View](/sl/documents/product-information/trulicity-epar-product-information_sl.pdf)

Suomi (FI) (2.44 MB - PDF)

**First published:**

19/12/2014

**Last updated:**

31/07/2025

[View](/fi/documents/product-information/trulicity-epar-product-information_fi.pdf)

svenska (SV) (1.67 MB - PDF)

**First published:**

19/12/2014

**Last updated:**

31/07/2025

[View](/sv/documents/product-information/trulicity-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** PSUSA/00010311/202409 23/07/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Trulicity : EPAR - All Authorised presentations

English (EN) (55.93 KB - PDF)

**First published:** 19/12/2014

**Last updated:** 19/05/2021

[View](/en/documents/all-authorised-presentations/trulicity-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-464)

български (BG) (97.46 KB - PDF)

**First published:**

19/12/2014

**Last updated:**

19/05/2021

[View](/bg/documents/all-authorised-presentations/trulicity-epar-all-authorised-presentations_bg.pdf)

español (ES) (21.75 KB - PDF)

**First published:**

19/12/2014

**Last updated:**

19/05/2021

[View](/es/documents/all-authorised-presentations/trulicity-epar-all-authorised-presentations_es.pdf)

čeština (CS) (59.37 KB - PDF)

**First published:**

19/12/2014

**Last updated:**

19/05/2021

[View](/cs/documents/all-authorised-presentations/trulicity-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (71.85 KB - PDF)

**First published:**

19/12/2014

**Last updated:**

19/05/2021

[View](/da/documents/all-authorised-presentations/trulicity-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (86.64 KB - PDF)

**First published:**

19/12/2014

**Last updated:**

19/05/2021

[View](/de/documents/all-authorised-presentations/trulicity-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (67.26 KB - PDF)

**First published:**

19/12/2014

**Last updated:**

19/05/2021

[View](/et/documents/all-authorised-presentations/trulicity-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (119.5 KB - PDF)

**First published:**

19/12/2014

**Last updated:**

19/05/2021

[View](/el/documents/all-authorised-presentations/trulicity-epar-all-authorised-presentations_el.pdf)

français (FR) (100.71 KB - PDF)

**First published:**

19/12/2014

**Last updated:**

19/05/2021

[View](/fr/documents/all-authorised-presentations/trulicity-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (77.81 KB - PDF)

**First published:**

19/12/2014

**Last updated:**

19/05/2021

[View](/hr/documents/all-authorised-presentations/trulicity-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (72.77 KB - PDF)

**First published:**

19/12/2014

**Last updated:**

19/05/2021

[View](/is/documents/all-authorised-presentations/trulicity-epar-all-authorised-presentations_is.pdf)

italiano (IT) (54.86 KB - PDF)

**First published:**

19/12/2014

**Last updated:**

19/05/2021

[View](/it/documents/all-authorised-presentations/trulicity-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (96.72 KB - PDF)

**First published:**

19/12/2014

**Last updated:**

19/05/2021

[View](/lv/documents/all-authorised-presentations/trulicity-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (122.47 KB - PDF)

**First published:**

19/12/2014

**Last updated:**

19/05/2021

[View](/lt/documents/all-authorised-presentations/trulicity-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (195.67 KB - PDF)

**First published:**

19/12/2014

**Last updated:**

19/05/2021

[View](/hu/documents/all-authorised-presentations/trulicity-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (72.31 KB - PDF)

**First published:**

19/12/2014

**Last updated:**

19/05/2021

[View](/mt/documents/all-authorised-presentations/trulicity-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (50.68 KB - PDF)

**First published:**

19/12/2014

**Last updated:**

19/05/2021

[View](/nl/documents/all-authorised-presentations/trulicity-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (105.47 KB - PDF)

**First published:**

19/12/2014

**Last updated:**

19/05/2021

[View](/no/documents/all-authorised-presentations/trulicity-epar-all-authorised-presentations_no.pdf)

polski (PL) (127.99 KB - PDF)

**First published:**

19/12/2014

**Last updated:**

19/05/2021

[View](/pl/documents/all-authorised-presentations/trulicity-epar-all-authorised-presentations_pl.pdf)

português (PT) (104.85 KB - PDF)

**First published:**

19/12/2014

**Last updated:**

19/05/2021

[View](/pt/documents/all-authorised-presentations/trulicity-epar-all-authorised-presentations_pt.pdf)

română (RO) (111.53 KB - PDF)

**First published:**

19/12/2014

**Last updated:**

19/05/2021

[View](/ro/documents/all-authorised-presentations/trulicity-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (73.25 KB - PDF)

**First published:**

19/12/2014

**Last updated:**

19/05/2021

[View](/sk/documents/all-authorised-presentations/trulicity-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (82.23 KB - PDF)

**First published:**

19/12/2014

**Last updated:**

19/05/2021

[View](/sl/documents/all-authorised-presentations/trulicity-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (67.32 KB - PDF)

**First published:**

19/12/2014

**Last updated:**

19/05/2021

[View](/fi/documents/all-authorised-presentations/trulicity-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (53.06 KB - PDF)

**First published:**

19/12/2014

**Last updated:**

19/05/2021

[View](/sv/documents/all-authorised-presentations/trulicity-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Trulicity Active substance dulaglutide International non-proprietary name (INN) or common name dulaglutide Therapeutic area (MeSH) Diabetes Mellitus, Type 2 Anatomical therapeutic chemical (ATC) code A10BJ05

### Pharmacotherapeutic group

- Drugs used in diabetes
- Blood glucose lowering drugs, excl. insulins

### Therapeutic indication

Trulicity is indicated for the treatment of patients 10 years and above with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise

- as monotherapy when metformin is considered inappropriate due to intolerance or contraindications
- in addition to other medicinal products for the treatment of diabetes.

For study results with respect to combinations, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1.

## Authorisation details

EMA product number EMEA/H/C/002825 Marketing authorisation holder

Eli Lilly Nederland B.V.

Papendorpseweg 83

Opinion adopted 25/09/2014 Marketing authorisation issued 21/11/2014 Revision 20

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Trulicity : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (276.54 KB - PDF)

**First published:** 08/09/2015

**Last updated:** 31/07/2025

[View](/en/documents/procedural-steps-after/trulicity-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Trulicity-H-C-2825-II-0065 : EPAR - Assessment report - Variation

Adopted

Reference Number: EMA/CHMP/21654/2023

English (EN) (2.67 MB - PDF)

**First published:** 16/03/2023

[View](/en/documents/variation-report/trulicity-h-c-2825-ii-0065-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of opinion for Trulicity (II-65)

Adopted

Reference Number: EMA/CHMP/26443/2023

English (EN) (107.79 KB - PDF)

**First published:** 27/01/2023

[View](/en/documents/smop/chmp-post-authorisation-summary-opinion-trulicity-ii-65_en.pdf)

Trulicity-H-C-PSUSA-10311-202009 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s)

Adopted

Reference Number: EMA/379387/2021

English (EN) (147.16 KB - PDF)

**First published:** 05/07/2021

[View](/en/documents/scientific-conclusion/trulicity-h-c-psusa-10311-202009-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations_en.pdf)

Trulicity-H-C-2825-X-0045 : EPAR - Assessment report - Variation

Adopted

Reference Number: EMA/572529/2020

English (EN) (3.9 MB - PDF)

**First published:** 01/02/2021

[View](/en/documents/variation-report/trulicity-h-c-2825-x-0045-epar-assessment-report-variation_en.pdf)

Trulicity-H-C-2825-II-0040 : EPAR - Assessment report - Variation

Adopted

Reference Number: EMA/585102/2019

English (EN) (1.88 MB - PDF)

**First published:** 08/11/2019

[View](/en/documents/variation-report/trulicity-h-c-2825-ii-0040-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Trulicity (II-40)

Adopted

Reference Number: EMA/504760/2019

English (EN) (137.96 KB - PDF)

**First published:** 20/09/2019

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-trulicity-ii-40_en.pdf)

Trulicity-H-C-PSUSA-00010311-201709 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/482538/2018

English (EN) (107.59 KB - PDF)

**First published:** 17/07/2018

**Last updated:** 17/07/2018

[View](/en/documents/scientific-conclusion/trulicity-h-c-psusa-00010311-201709-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Trulicity-H-C-PSUSA-10311-201609 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/392717/2017

English (EN) (103.83 KB - PDF)

**First published:** 04/07/2017

**Last updated:** 04/07/2017

[View](/en/documents/scientific-conclusion/trulicity-h-c-psusa-10311-201609-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Trulicity : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

English (EN) (16.03 KB - PDF)

**First published:** 15/12/2016

**Last updated:** 15/12/2016

[View](/en/documents/scientific-conclusion/trulicity-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Trulicity : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/524604/2014

English (EN) (4.23 MB - PDF)

**First published:** 19/12/2014

**Last updated:** 19/12/2014

[View](/en/documents/assessment-report/trulicity-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Trulicity

Adopted

Reference Number: EMA/CHMP/524609/2014

English (EN) (87.53 KB - PDF)

**First published:** 26/09/2014

**Last updated:** 26/09/2014

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-trulicity_en.pdf)

#### News on Trulicity

[Warning about sharp rise in illegal medicines sold in the EU](/en/news/warning-about-sharp-rise-illegal-medicines-sold-eu) 03/09/2025

[EU actions to tackle shortages of GLP-1 receptor agonists](/en/news/eu-actions-tackle-shortages-glp-1-receptor-agonists) 26/06/2024

[Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 8-11 April 2024](/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-8-11-april-2024) 12/04/2024

[EMA statement on ongoing review of GLP-1 receptor agonists](/en/news/ema-statement-ongoing-review-glp-1-receptor-agonists) 11/07/2023

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 January 2023](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-23-26-january-2023) 27/01/2023

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 September 2019](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-16-19-september-2019) 20/09/2019

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 September 2014](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-september-2014) 26/09/2014

#### More information on Trulicity

- [EMEA-000783-PIP01-09-M06 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-000783-pip01-09-m06)
- [Trulicity - supply shortage](/en/medicines/human/shortages/trulicity)
- [Dulaglutide and Potential Risks of Pancreatic Cancer and Thyroid Cancer: A Non-Interventional PASS (H9X-MC-B013) - post-authorisation study](https://catalogues.ema.europa.eu/study/49022)
- [DARWIN EU® - Drug Utilisation Study on GLP-1 Receptor Agonists - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000223)
- [Dulaglutide Modified-Prescription-Event Monitoring Study and network database study: a multi-database collaborative research program of observational studies to monitor the utilisation and safety of dulaglutide in the EU - post-authorisation study](https://catalogues.ema.europa.eu/study/44227)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 31/07/2025

## Share this page

[Back to top](#main-content)